Jurisdictional guides

This subtopic provides a range of international guidance.

The Lexology Panoramic guides, curated by leading lawyers and law firms, provide a view of laws and regulations in multiple jurisdictions

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

Commission opens consultation on circular bioeconomy initiative

The European Commission has launched a call for evidence on its new circular bioeconomy initiative, open from 31 March 2025. The initiative, presented as a Communication under the Commission Work Programme, aims to support sustainable biomass use across agriculture, forestry, fisheries, biomanufacturing and biotechnology sectors. The proposal focuses on maintaining materials and products within the economy while operating within environmental constraints. Stakeholders can submit feedback through the Commission's online consultation platform, with all responses to be published publicly. The consultations closes on 23 June 2025.

UPC likely to lure patent holders with UK IP in play

Law360, London: The Unified Patent Court (UPC) has now doubled down on its authority to hear claims involving UK patents, a move that is likely to make the court an even more desirable forum for global infringement actions.

How new EU Product Liability Directive will affect tech and AI

Law360, London: The EU has taken a significant step forward in modernising its liability framework with the adoption of a new Product Liability Directive in October 2024, effective from 9 December 2026.

Court of Justice clarifies the applicability of medicines advertising legislation to discounts (Apothekerkammer Nordrhein)

Life Sciences analysis: The Court of Justice provided clarification of the meaning of ‘advertising of medicinal products’ under Directive 2001/83 (the Directive), in the context of various promotional schemes offered by pharmacists. It stated that the offer of discounts or payments on the purchase of unspecified prescription-only medicines (POMs), merely influences the choice of pharmacy from which a customer purchases such medicines and does not constitute advertising within the scope of the Directive. In contrast, advertising measures that reward the purchase of unspecified POMs by providing vouchers for the subsequent purchase of non-prescription medicines, promotes such subsequent purchases and is therefore categorized as advertising under the Directive. The court also considered whether restrictions on promotional schemes for medicines advertised electronically are consistent with EU law on free movement of goods and e-commerce. It confirmed that, despite their greater impact on mail order pharmacies established in other Member States, such restrictions could nevertheless be permissible when introduced for protection of public health. Written by Adela Williams, partner and Heba Jalil, associate at Arnold & Porter.